3-Isopropyl-2-norbornanamin | 25220-12-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-Isopropyl-2-norbornanamin
• 英文别名: 3-Isopropyl-bicyclo[2.2.1]hept-2-ylamine；3-propan-2-ylbicyclo[2.2.1]heptan-2-amine
• CAS: 25220-12-6
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: SHXVJSFOJHMEEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130369A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。
• [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：RIDEOUT DARRYL

  公开号：WO2016105448A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物，如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物，有些实施例中还提供了对其的调节剂（例如，激动剂）。
• [EN] COMPOUNDS FOR USE AS PAIN THERAPEUTICS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LA DOULEUR
  申请人：LEDERMAN SETH

  公开号：WO2016105449A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibromyalgia-ness; central sensitization; centralization; regional pain syndrome; temporomandibular joint syndrome (TMJ); lower back pain; interstitial cystitis; Gulf War syndrome; visceral pain; phantom limb painj.kidney stones; gout; neuropathic pain; post-herpetic neuralgia; diabetic neuropathy; sickle cell pain; priapism; nociceptive pain; post-operative pain; orthopedic injury pain; bunionectomy; dental extraction; pain after severed spinal cord injury; osteoarthritis; rheumatoid arthritis; Lyme disease; Parkinson's disease; opioid-induced constipation; an opioid withdrawal symptom; pain associated with post-traumatic stress disorder (PTSD); and combinations of any of the foregoing conditions. This disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了用作镇痛剂和用于治疗以下一种或多种疾病的化合物和组合物：疼痛；心理疼痛；心理疼痛；精神疼痛；抑郁症；痛觉过敏；纤维肌痛；纤维肌痛症；中枢敏感化；中枢化；区域性疼痛综合征；颞下颌关节综合征（TMJ）；腰部疼痛；间质性膀胱炎；海湾战争综合征；内脏疼痛；幻肢疼痛；肾结石；痛风；神经性疼痛；带状疱疹后神经痛；糖尿病性神经病；镰状细胞疼痛；阴茎长时间勃起症；伤害性疼痛；术后疼痛；骨科损伤疼痛；拇外翻术；牙科拔牙；断裂脊髓损伤后疼痛；骨关节炎；类风湿关节炎；莱姆病；帕金森病；阿片类药物引起的便秘；阿片类药物戒断症状；与创伤后应激障碍（PTSD）相关的疼痛；以及上述任何疾病的组合。本公开还提供了作为咪唑啉受体类型1的配体的化合物，有些实施例中是调节剂（例如，激动剂）。
• NOVEL AMINO-PYRROLINE DERIVATIVES, AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF METABOLIC SYNDROME
  申请人：Bousquet Pascal

  公开号：US20140045910A1

  公开（公告）日：2014-02-13

  Novel amino-pyrrolinic derivatives, their pharmacologically acceptable salts and use thereof in the prevention and/or treatment of metabolic syndrome.

  新型氨基吡咯烷衍生物，其药理学上可接受的盐和在预防和/或治疗代谢综合征中的应用。
• [EN] AGENTS FOR REVERSING TOXIC PROTEINOPATHIES<br/>[FR] AGENTS POUR INVERSER DES PROTÉINOPATHIES TOXIQUES
  申请人：BROAD INST INC

  公开号：WO2020257736A1

  公开（公告）日：2020-12-24

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

  本公开涉及诊断和治疗或预防蛋白质病变的组合物和方法，特别是与MUC1相关的肾脏疾病（ADTKD-MUC1或MKD）、视网膜色素变性（例如由于视紫红质突变引起）、由UMOD突变引起的常染色体显性小管间质肾病（ADTKD-UMOD）以及由突变蛋白在内质网或其他分泌途径间室和/或囊泡中积累导致的其他形式的有毒蛋白病变等。本公开还确定并提供了TMED9结合剂，作为治疗或预防分泌途径蛋白病变的能力，并进一步提供了识别其他TMED9结合剂的方法。